Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ESPR vs SIGA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ESPR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

ESPR Overall Winner 6-Pillar Tally: ESPR 5 – 1 SIGA Matrix Metrics: ESPR 7 – 3 SIGA

As of Nov 20, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ESPR carries a Unified Composite Score of 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin), whereas SIGA carries 46.2/100 (HOLD) at $2.40 (2.3x Forward P/E, -14.2% operating margin).

  • Technical & Structure Timing Caution: ESPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.5); meanwhile SIGA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ESPR vs SIGA
ESPR NASDAQ Head-to-Head Winner
Esperion Therapeutics, Inc.
Pharmaceutical Preparations
$3.18
-0.31% 1D
Market Cap $822.0M
TTM Revenue $418M
Forward P/E 10.9x
Beta / 30D Vol 1.86β · 6% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 64.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.5% over 20 days), RSI 64
RSI-14: 63.5 · SMA20: $3.16 · SMA50: $3.10
SIGA NASDAQ
SIGA Technologies Inc.
Pharmaceutical Preparations
$2.40
-9.43% 1D
Market Cap $188.3M
TTM Revenue $52M
Forward P/E 2.3x
Beta / 30D Vol 0.90β · 74% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 33.0 Fund 53.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.2%), weak momentum, RSI 31
RSI-14: 31.0 · SMA20: $2.99 · SMA50: $3.13

6-Pillar Scorecard Institutional Category Breakdown (ESPR 5 – 1 SIGA)

Columns: Metric · ESPR · SIGA
1. Valuation Multiples SIGA
Forward P/E 10.9x 2.3x
Trailing P/E 4.6x N/M
PEG Ratio N/M 3.37x
EV / Revenue 2.2x 1.4x
2. Growth & Scale ESPR
Revenue Growth (YoY) +23.2% -49.7%
Earnings Growth (YoY) +0.0% -65.3%
TTM Revenue (USD) $418M $52M
Market Cap $822.0M $188.3M
3. Profitability & Quality ESPR
Gross Margin 57.8% 23.4%
Operating Margin -8.2% -14.2%
Net Profit Margin -1.8% 1.3%
Return on Equity (ROE) -260.8% 0.4%
4. Balance Sheet & Cash Flow ESPR
Cash Generation (TTM) -$18M -$12M
Cash Flow Margin -4.4% -22.1%
Net Cash / Leverage $96M Net Debt $116M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ESPR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 12.5% (9th %ile) 94.8% (6th %ile)
Put/Call OI Skew N/A 0.50x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ESPR
OpEx & R&D Intensity 66.0% of Rev ($276M) 37.6% of Rev ($20M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ESPR (7) vs SIGA (3)
Institutional Metric ESPR SIGA Criterion Row Edge
Market Capitalization
Scale
$822.0M $188.3M Larger Scale ESPR
Trailing P/E Ratio
Valuation
4.6x N/M Lower Multiple ESPR
Forward P/E Ratio
Valuation
10.9x 2.3x Lower Multiple SIGA
Revenue Growth (YoY)
Growth
+23.2% -49.7% Higher Growth ESPR
Operating Margin (TTM)
Profitability
-8.2% -14.2% Higher Margin ESPR
Net Profit Margin
Profitability
-1.8% 1.3% Higher Margin SIGA
Return on Equity (ROE)
Capital Efficiency
-260.8% 0.4% Higher ROE SIGA
52-Week Range Position
Momentum
68% ($1–$4) 2% ($2–$7) Stronger Trend ESPR
Beta / 30D Volatility
Risk Regime
1.86β · 6% Vol 0.90β · 74% Vol Lower Realized Risk ESPR
Unified Institutional Score
Composite Signal
60.0 / 100 (BUY) 46.2 / 100 (HOLD) Higher Composite ESPR
Trailing 12M Revenue (USD)
Operating Scale
$418M $52M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
57.8% 23.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.2x EV/Rev 3.37x PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$18M ($96M Net Debt) -$12M ($116M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ESPR +19.49 pp
ESPR: +1.27% · SIGA: -18.22%
3M Horizon ESPR +64.28 pp
ESPR: +45.87% · SIGA: -18.41%
6M Horizon ESPR +30.4 pp
ESPR: -17.19% · SIGA: -47.59%
1Y Horizon ESPR +53.24 pp
ESPR: +13.98% · SIGA: -39.26%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ESPR Revenue SIGA Revenue ESPR Op. Margin SIGA Op. Margin Margin Leader
FY2018 N/A $480M N/A 74.4% SIGA
FY2019 $150M $30M -62.8% -8.7% SIGA
FY2020 $230M $120M -53.3% 67.6% SIGA
FY2021 $80M $130M -289.0% 66.7% SIGA
FY2022 $80M $110M -237.8% 38.5% SIGA
FY2023 $120M $140M -133.7% 59.8% SIGA
FY2024 $330M $140M 16.4% 50.4% SIGA
FY2025 $400M $90M 15.0% 25.1% SIGA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ESPR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 12.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ESPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SIGA BREAKDOWN
34d in phase · OBV DISTRIBUTION
Current IV 94.8%
IV Percentile 6th %ile
Put/Call OI Skew 0.50x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIGA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ESPR Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $822.0M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 66.0% of Rev ($276M)
90D Engineering Disclosures 0 Published
SIGA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $188.3M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($20M)
90D Engineering Disclosures 0 Published

Investor FAQ ESPR vs SIGA Key Questions & Quantitative Answers

As of Nov 20, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ESPR carries a Unified Composite Score of 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin), whereas SIGA carries 46.2/100 (HOLD) at $2.40 (2.3x Forward P/E, -14.2% operating margin). Technical & Structure Timing Caution: ESPR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.5); meanwhile SIGA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ESPR leads the Growth & Scale pillar: ESPR posts +23.2% YoY revenue growth and +0.0% YoY earnings growth on $418M TTM revenue (57.8% gross margin, -8.2% operating margin), compared with SIGA at -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ESPR cumulative revenue shifted +166.7% while SIGA shifted -81.2%. In operating R&D and SG&A reinvestment, ESPR deploys 66.0% of Rev ($276M) (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($20M) (0 disclosures) for SIGA.

SIGA screens cheaper on headline valuation multiples. ESPR trades at 10.9x Forward P/E, 4.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (-4.4% FCF margin), whereas SIGA trades at 2.3x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ESPR (-260.8% ROE) versus SIGA (0.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ESPR carries 12.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.86β · 6% Vol realized risk). By comparison, SIGA carries 94.8% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.90β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.